BACKGROUND: Serum antibodies to myelin-oligodendrocyte glycoprotein (MOG) are biomarkers of MOG-IgG-associated disorder (MOGAD), a demyelinating disease distinct from both multiple sclerosis and aquaporin-4-IgG neuromyelitis optica spectrum disorder. The phenotype of MOGAD is broad and includes optic neuritis, transverse myelitis, and acute demyelinating encephalomyelitis. Myelitis is common with MOGAD and typically results in acute and severe disability, although prospects for recovery are often favorable with prompt immunotherapy. CASE PRESENTATION: This contribution presents a unique case report of a young male patient exhibiting relapsing myelitis with normal spinal cord and brain magnetic resonance imaging. Comprehensive diagnostic assessment revealed myelin-oligodendrocyte glycoprotein-IgG-associated disorder. CONCLUSION: MOGAD is one of the conditions which should be considered in MRI-negative myelitis. The diagnosis, however, may prove difficult, especially if the patient is not exhibiting other neurological symptoms of MOGAD. Conus or epiconus involvement is common in MOGAD; the patient reported herein exhibited incomplete rostral epiconus symptoms which, together with somatosensory evoked potential abnormalities, led to the diagnosis.

Department of Neurology University Hospital Brno Brno Czech Republic

ERN Neuromuscular Center Euro NMD University Hospital Brno Jihlavská 340 20 625 00 Brno Stary Liskovec Brno Bohunice Czech Republic

Faculty of Medicine Masaryk University Brno Brno Czech Republic

See more in PubMed

Banks SA, Morris PP, Chen JJ, Pittock SJ, Sechi E, Kunchok A, et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. 2021;92:348–8. doi: 10.1136/jnnp-2020-325121. PubMed DOI PMC

Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019;76:301–9. doi: 10.1001/jamaneurol.2018.4053. PubMed DOI PMC

Clerici AM, Nobile-Orazio E, Mauri M, Squellati FS, Bono GG. Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long-lasting case of chronic immune sensory polyradiculopathy. BMC Neurol. 2017;17:127. doi: 10.1186/s12883-017-0906-2. PubMed DOI PMC

Van den Bergh PYK, Hadden RDM, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17:356–63. doi: 10.1111/j.1468-1331.2009.02930.x. PubMed DOI

Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267:3565–77. doi: 10.1007/s00415-020-10026-y. PubMed DOI PMC

Sechi E, Krecke KN, Pittock SJ, Dubey D, Lopez-Chiriboga AS, Kunchok A, et al. Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Mult Scler. 2021;27(2):303–8. doi: 10.1177/1352458520907900. PubMed DOI PMC

Macaron G, Ontaneda D. MOG-related disorders: A new cause of imaging-negative myelitis? Mult Scler. 2020;26:511–5. doi: 10.1177/1352458519840746. PubMed DOI

Grangeon L, Hébant B, Guillaume M, Ahtoy P, Lefaucheur R. Myelitis with normal spinal cord MRI: don’t forget anti-MOG antibodies disease! Acta Neurol Belg. 2020;120:945–6. doi: 10.1007/s13760-020-01327-0. PubMed DOI

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279. doi: 10.1186/s12974-016-0717-1. PubMed DOI PMC

Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, et al. Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. J Neurol Neurosurg Psychiatry. 2019;90(4):488–90. doi: 10.1136/jnnp-2018-318004. PubMed DOI

Zalewski NL, Rabinstein AA, Krecke KN, Brown RD, Jr, Wijdicks EFM, Weinshenker BG, et al. Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria. JAMA Neurol. 2019;76(1):56–63. doi: 10.1001/jamaneurol.2018.2734. PubMed DOI PMC

Hardmeier M, Leocani L, Fuhr P. A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. Mult Scler. 2017;23:1309–19. doi: 10.1177/1352458517707265. PubMed DOI PMC

Dula AN, Pawate S, Dortch RD, Barry RL, George-Durrett KM, Lyttle BD, et al. Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis at 7T. Mult Scler. 2016;22:320–8. doi: 10.1177/1352458515591070. PubMed DOI PMC

Sechi E, Krecke KN, Messina SA, Buciuc M, Pittock SJ, Chen JJ, et al. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology. 2021;97(11):e1097–109. doi: 10.1212/WNL.0000000000012467. PubMed DOI PMC

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology. 2018;90:e1858–69. doi: 10.1212/WNL.0000000000005560. PubMed DOI

Lopez-Chiriboga AS, Sechi E, Buciuc M, Chen JJ, Pittock SJ, Lucchinetti CF, et al. Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder. JAMA Neurol. 2020;77(12):1575–7. doi: 10.1001/jamaneurol.2020.3115. PubMed DOI PMC